EPHA2 and cancer: In this study, we aimed to develop a cationic solid lipid nanoparticle/siRNA complex targeting EphA2 receptor (cSLN/siEphA2 complex) for use in the treatment of advanced cancers with high levels of EphA2 expression and investigate its anticancer activity alone and in combination with a pan-KDM inhibitor JIB-04 for prostate cancer therapy in vitro.